Home » Stocks » PRLD

Prelude Therapeutics, Inc. (PRLD)

Stock Price: $74.99 USD 0.56 (0.75%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 3.47B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 3.19M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $74.99
Previous Close $74.43
Change ($) 0.56
Change (%) 0.75%
Day's Open 74.01
Day's Range 71.86 - 77.08
Day's Volume 304,567
52-Week Range 26.20 - 88.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced ...

GlobeNewsWire - 2 weeks ago

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision...

GlobeNewsWire - 3 weeks ago

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced ...

GlobeNewsWire - 2 months ago

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M -

GlobeNewsWire - 3 months ago

WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has b...

GlobeNewsWire - 3 months ago

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial...

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, GRAY, LSF, PMVP, ARRY
GlobeNewsWire - 4 months ago

WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial...

Seeking Alpha - 4 months ago

Prelude Therapeutics has filed to raise $150 million in a U.S. IPO.

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is als... [Read more...]

Industry
Biotechnology
IPO Date
Sep 25, 2020
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Employees
55
Stock Exchange
NASDAQ
Ticker Symbol
PRLD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PRLD stock is "Hold." The 12-month stock price forecast is 48.00, which is a decrease of -35.99% from the latest price.

Price Target
$48.00
(-35.99% downside)
Analyst Consensus: Hold